Fluidosomes Tobramycin regulatory update

FDA granted Orphan Drug designation for Axentis' Fluidosomes Tobramycin to treat pulmonary infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis (CF). The fluid liposomal-tobram...